Molecular targeted agents have enriched the therapeutic options. The VEGF inhibitor bevacicumab has no single agent activity. It was studied in several phase III chemotherapy trials. The best results were achieved when bevacizumab was combined with fluoropyrimidies (infusional 5-FU and capecitabine) alone or with IFL (bolus 5-FU), while randomized data for the infusional schedule FOLFIRI is missing and data on FOLFOX is negative. The EGF receptor antibodies cetuximab or panitumumab have single agent activity but are only active in k-ras wt tumors. In combination with FOLFIRI or FOLFOX they can improve RR, PFS and OS according to randomized trials. For the use of targeted agents clinicians have to determine the treatment strategy. If cure is the aim or a rapid relieve of tumor related symptoms in aggressive tumors is necessary regimens inducing a high RR such as FOLFOXIRI or FOLFOX / FOLFIRI plus an EGFR antibody are optimal. The treatment of patients with a slow tumor progression or a low tumor burden may start with 5-FU or capecitabine alone of in combination with bevacizumab. According to recently published data of the CRYSTAL study FOLFIRI plus cetuxcimab is also an options in k-ras wt tumors as this is the only regimen that prolongs survival statistically significant and clinically relevant. FOLFOX should not be combined with an EGFR antibody in k-ras mut tumors and combinations of EGFR and VEGF antibodies in combinations with chemotherapy should be avoided outside a clinical trial, as inferior outcomes have been observed.
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introduction
With the introduction of irinotecan and oxaliplatin and more recently agents targeting the vascular endothelial growth factor (VEGF)-mediated angiogenesis pathway and those targeting the epidermal growth factor (EGF)-mediated growth regulatory pathway substantial advances were achieved in the treatment of metastatic colorectal cancer [1] . Long-term survival of >4 years is reported in 30% of patients. In addition, more surgery in patients with metastases especially after conversion chemotherapy can result in cure in a substantial number of patients. In this article the intergration of biological agents in the different treatment strategies and different clinical presentations of patients are discussed.
chemotherapy plus bevacizumab
VEGF is a diffusible glycoprotein with several different isoforms, termed VEGF-A, VEGF-B, VEGF-C and VEGF-D. VEGF-A binds to two related tyrosine kinase receptors, termed VEGFR-1 and VEGFR -2. Bevacizumab, which has a high binding affinity to VEGF, interferes with binding of VEGF-A to VEGFR-1 and VEGFR-2, thus inhibiting VEGF-mediated intracellular signalling [2] . In early experiemental work on colon cancer specimens, investigators noted a correlation between increased VEGF expression and metastatic and proliferative activity in tumours.
In two publications (Table 1 ) the relative activity of bevacizumab when added to a fluoropyrimidine was reported. Kabbinavar and colleagues [4] performed a combined analysis of three small independent studies that included 249 patients receiving bevacizumab and 5FU plus leucovorin and 241 patients in a combined control group receiving either 5FU plus leucovorin alone or irinotecan and 5FU plus leucovorin bolus (IFL). Bevacizumab produced a signficiant improvement over placebo in terms of progression-free survival (PFS) (8.8 months versus 5.6 months; P < 0.0001), overall survival (OS) (17.9 months versus 14.6 months; P = 0.008) and response rate (34% versus 25%; P = 0.19).
More recently, Tebbutt and colleagues [6] reported on a comparison of capecitabine alone versus capecitabine plus bevacizumab in 319 patients. Bevacizumab improved the PFS from 5.7 to 8.5 months (P < 0.001), but had no impact on the median OS (18.9 months versus 18.9 months). Following these reports bevacizumab added to a fluoropyrimidine has gained acceptance as a first-line treatment option for metastatic colorectal cancer patients.
Bevacizumab has also been added to the IFL regimen [3] . A total of 813 patients received the IFL regimen either alone or in combination with bevacizumab ( Table 1 ). The response rate of 45% versus 35% (P = 0.004) and the PFS of 6.2 versus 10.6 months (P < 0.001) and the median OS of 15.6 versus 20.3 months (P < 0.001) all indicated a substantial improvement in favour of the bevacizumab combination. However, the IFL regimen is no longer considered an optimal chemotherapy regimen. It is only as efficacious as infusional 5FU/folinic acid (FA) alone and infusional 5FU plus irinotecan (FOLFIRI regimen) is even better [7] . The IFL regimen also turned out to be more toxic than other regimens. Unfortunately, a direct comparison of FOLFIRI +/-bevacizumab is lacking although phase II data of infusional 5FU, irinotecan and bevacizumab resulted in a response rate of 65%, median PFS of 12.8 months and a median OS of 31.3 months [8] . When a modified IFL regimen plus bevacizumab was compared with FOLFIRI plus bevacizumab the median survival was clearly in favour of the infusional regimen (28 versus 19 months) [9] .
Saltz and coworkers [5] reported on a randomized trial including 401 patients who received either capecitabine plus oxaliplatin (XELOX) or infusional 5FU plus oxaliplatin (FOLFOX regimen). In a 2 · 2 factorial design bevacizumab or placebo was added to the XELOX or the FOLFOX regimen. When the regimens without or with bevacizumab were compared, there was no difference in the objective response rate, which was 38% in both arms. A moderate increase in PFS from 8.0 to 9.4 months was noted (P = 0.0023), while the OS was not significantly different (19.9 versus 21.3 months). The picture is different if all four arms of these studies are analysed separately. Here bevacizumab appeared to improve the XELOX regimen [hazard ratio (HR) 0.77, P = 0.0026] while there was no difference for the FOLFOX regimen (HR 0.89; P = 0.187). Indeed, XELOX plus bevacizumab had a similar PFS to the FOLFOX regimen alone. It is for this reason that FOLFOX plus bevacizumab has not gained broad acceptance as a first-line combination in Europe as it has in the USA. One may speculate that bevacizumab has best activity when added to suboptimal chemotherapy (5FU/FA, capecitabine or IFL).
Strong data for second-line use of bevacizumab in combination with the FOLFOX4 regimen were reported in the E3200 study from the Eastern Cooperative Oncology Group [10] (see Table 5 ). A total of 829 patients were randomized to receive bevacizumab alone, FOLFOX or FOLFOX plus bevacizumab. In this study the dose of bevacizumab was twice the dose usually used in first-line studies (10 instead of 5 mg/kg). The response rate in patients receiving bevacizumab alone was only 3%, but was 9% and 23%, respectively, for patients receiving FOLFOX or FOLFOX plus bevacizumab (P < 0.0001). Also, the median PFS was higher in the FOLFOX plus bevacizumab than in the FOLFOX-alone arm (7.3 compared with 4.7 months) and only 2.7 months in the bevacizumab-alone arm (P > 0.0001). This difference translated into an OS benefit only for those patients receiving FOLFOX plus bevacizumab (12.9 months versus 10.8 and 10.2 months; P = 0.001). Why bevacizumab plus FOLFOX resulted in a different outcome in the first-line setting as compared with second-line treatment is unknown. It does not seem likely that the higher bevacizumab dose added to the efficacy, as in an earlier small randomized first-line phase II study in combination with with a fluoropyrimidine alone, the higher bevacizumab dose did not result in a higher response rate [4] .
chemotherapy plus an epidermal growth factor receptor antibody
The immunglobulin G1 monoclonal antibody against the epidermal growth factor receptor (EGFR) cetuximab and the full human monoclonal antibody panitumumab are both active in patients with metastatic colorectal cancer, but efficacy is only seen on KRAS wild-type tumours [11] (Table 2) .
In contrast to bevacizumab, cetuximab and panitumumab started their developement in patients refractory to conventional chemotherapy (see Table 5 ). In the landmark Bowel Oncology With Cetuximab Antibody (BOND) study [16] patients refractory to irinotecan were randomized to receive cetuximab alone or in combination with irinotecan (the drug they had been refractory to!). The response rate was significantly higher in the combination arm (22% versus 11%; P = 0.007) and the median time to progression was also prolonged (1.5 to 4.1 months; P < 0.001). Cetuximab was further studied [17] in patients who had progressed after receiving a fluoropyrimidine, irinotecan and oxaliplatin and was compared with best supportive care alone. This study demonstrated a significant prolongation of OS for the cetuximab combination (4.6 to 6.1 months; HR 0.68; P < 0.001). In a similar study [17, 18] panitumumab failed to demonstrate an OS benefit most likely due to a cross-over to the antibody [18, 19] when best supportive care patients had progressive disease. When the analysis was restricted to patients with wild-type KRAS tumours the PFS was 12.3 versus 7.4 months (P < 0.001) in favour of those patients treated with panitumumab.
In the erbitux plus irinotecan for metastatic colorectal cancer (EPIC) study [20] 1298 patients who had failed first-line fluoropyrimidine plus oxaliplatin treatment were randomized to receive cetuximab and irinotecan or irinotecan alone. The response rate was significantly higher (16% versus 4%) and the PFS (4.0 versus 2.6 months) significantly prolonged in favour of cetuximab, but the OS times were comparable between the two regimens (10.7 and 10.0 months, respectively), probably because nearly 50% of patients assigned to irinotecan monotherapy later received cetuximab as well. Peeters and colleagues [21] studied the effect of FOLFIRI +/-panitumumab in patients pretreated with a FOLFOX regimen. The PFS (5.9 [6] versus 3.9 months; P = 0.004) and OS (14.5 versus 12.5 months; P = 0.12) both favoured the panitumumab arm. Objective response rate as a secondary end point was higher in the panitumumab arm (35% versus 10%). Based on these promising results in pretreated patients EGFR antibodies were tested in first line. In the cetuximab combined with irinotecan in first-line therapy for metastatic colorectal cancer (CRYSTAL) study [12] 1217 patients were randomly assigned to receive either cetuximab plus FOLFIRI or FOLFIRI alone. When the analysis was restricted to KRAS wild-type patients (n = 666) the response rate was significantly higher for those patients also receiving cetuximab (57 versus 40%; P < 0.0001) and the PFS (9.9 versus 8.4 months; P = 0.0012) and the median OS (20.0 versus 23.5 months; P = 0.0093) were both longer. This was actually the first report that a targeted agent, when added to an active and optimal chemotherapy backbone, was able to prolong survival in colorectal cancer.
Cetuximab was also studied in combination with the FOLFOX regimen in the smaller OPUS study [13] . Patients with KRAS wild-type tumours receiving FOLFOX alone had on objective response rate of 34% and a median PFS of 7.2 months as compared with a response rate of 57% and an 8.3-month PFS for patients receiving FOLFOX plus cetuximab (P < 0.001 and P = 0.028, respectively). In the larger PRIME study [15] previously untreated patients received either FOLFOX alone or FOLFOX in combination with panitumumab. The progressions free survival (primary end point) was longer for the combination treatment (8.0 versus 9.5 months, HR 0.8; P = 0.02). The higher objective response rate for the combination chemotherapy of 55% versus 48% was not statistically significant. The OS was in favour of the combination treatment (23.9 versus 19.7 months; HR 0.83; P = 0.07). Although failing to achieve a stastically difference in the OS this study supports the results observed in the CRYSTAL study.
Recently, the results of the COIN-trial were reported [14] . In this study investigators were free to chose the CAPOX or FOLFOX regimen and patients were randomized to receive cetuximab in addition to chemotherapy. The objective response rate favoured the cetuximab arm (50% versus 59%; P = 0.015) in wild-type KRAS tumours. However, the median PFS (8.6 versus 8.6; P = 0.60) and the OS (17.9 versus 17.0; P = 0.68) were not statistically significantly different. About two-thirds of the patients received the CAPOX regimen. A subgroup analysis suggested an interaction between the XELOX and the FOLFOX backbone: efficacy was seen when cetuximab was added to the modified FOLFOX regimen while in combination with XELOX, patients had an even worse outcome as compared with XELOX alone.
The results of the EGFR antibody studies in first line may be summarized as follows: cetuximab in combination with a FOLFIRI regimen improves the objective response rate and prolongs PFS and OS significantly in KRAS wild-type tumours. The picture is less clear for oxaliplatin-containing regimens although EGFR antibodies improve the FOLFOX regimen. The chemotherapy backbone matters, with a negative interaction between EGFR antibodies and oxaliplatin observed in patients with KRAS mutant tumours and also with capecitabine and KRAS wild-type tumours (Table 3) .
chemotherapy plus bevacizumab and an EGFR antibody
As outlined in Table 4 two studies used chemotherapy plus bevacizumab as a control regimen to which cetuximab or panitumumab was added in the experimental arm.
In the CAIRO2 study [22] patients received CAPOX plus bevacizumab alone or in combination with cetuximab. In KRAS wild-type patients there was no increase in the objective response rate (50% versus 61%; P = 0.06) and no prolongation of the progression free (10.6 versus 10.5 months; P = 0.30) or OS (22.4 versus 21.8 months; P = 0.64). For KRAS mutant tumours a stastically significant detrimental effect was observed when cetuximab was added to the oxaliplatin regimens with a lower objective response rate, a shorter PFS and shorter median OS (Table 3) . This was also observed in the PACCE study [23] in which patients received either FOLFOX or FOLFIRI according to the physicians' choice in combination with bevacizumab, and panitumumab was added in the experimental arm. In patients with KRAS wild-type tumours the response rate, median progression free and OS were all not statistically significant while there was a shorter PFS for those patients treated with FOLFOX, bevacizumab and panitumumab as compared with patients receiving the FOLFOX regimen plus bevacizumab alone (Table 4) . These results were partly confirmed in those patients who received FOLFIRI instead of FOLFOX. Based on the results of the two studies simultaneous use of the two antibodies should currently be avoided.
how to integrate these results into clinical practice
Before choosing the first-line regimen the clinician has to determine the treatment strategy. If cure is the aim by reducing the tumour size to allow surgery thereafter a more aggressive regimen may be used while quality of life becomes more important in those patients who have a purely palliative approach. With more efficacious chemotherapy regimens combined with targeted agents a strategy once palliative may be converted into a curative one.
It will be necessary to discuss the different clinical presentations and treatment strategies when integrating biologicals into chemotherapy regimens.
therapy of patients with a curative approach
Patients with unresectable metastases may become resectable after tumour shrinkage (conversion chemotherapy). The more efficacious the treatment, i.e. the higher the response rate, the more R0 resections are possible [24] . Therefore, a regimen resulting in a high objective response rate is most suitable in this respect. Although bevacizumab was able to increase the objective response rate in the IFL regimen there was no increase in the objective response rate when bevacizumab was added to the more optimal infusional FOLFOX regimen and data for FOLFIRI +/-bevacizumab are lacking. Therefore bevacizumab does not seem to be the optimal partner for chemotherapy in this strategy. On the contrary, most studies using an EGFR antibody resulted in an increased objective response rate and [25] . In this experience 109 patients were randomized to receive FOLFOX plus cetuximab or FOLFIRI plus cetuximab. The objective response rate in KRAS wild-type tumours was 70% for both regimens. An R0 resection was possible in 34% with an additional 14% of patients in which either an R1 resection or radiofrequency ablation was possible. Based on this experience chemotherapy combined with an EGF receptor antibody, in this case cetuximab, appears to be the most optimal approach in this subgroup of patients and both, FOLFIRI and FOLFOX regimens are valid chemotherapy backbones.
treatment for patients with tumourrelated symptoms or rapidly progressive disease
Clinicians are well aware of this subgroup of patients, which however, has not been adressed specifically in prospective randomized trials. Probably some of these patients are included in the group of performance status (PS) 2 patients who should receive combination chemotherapy [26] . In fact, the increment in OS appeared to be larger for PS 2 than for PS 0-1 patients when FOLFIRI or FOLFOX was compared with infusional 5FU/ FA alone. Whether cetuximab or panitumumab should be added to FOLFIRI or FOLFOX in PS 2 patients is unclear. Unfortunately, only a minority of this subgroup was included in the CRYSTAL or PRIME study and a subgroup analysis rather favoured the control than the experimental arm. As prospective randomized studies for this group of patients are currently lacking, physicians have to take a careful decision when choosing a combination with a biological in these patients.
On the other hand, patients with rapidly progressive disease may have only one chance to control tumour growth in order to prevent rapid deterioration. Subgroup analysis of the CAIRO [27] and FOCUS [28] studies indicates that upfront combination chemotherapy should be preferred over sequential therapy in patients with unfavourable prognostic factors. As the addition of cetuximab results in a higher objective response rate at least in patients with KRAS wild-type tumours this antibody may very likely further improve the results in this subgroup of patients. As the combination with bevacizumab at least together with the FOLFOX regimen does not result in a higher objective response rate it is questionable whether this is the optimal option in these patients or whether a combination with the FOLFOXIRI regimen if at all suitable in patients with KRAS mutant tumours could be a better choice. treatment for patients with slow tumour progression or low tumour burden This group of patients is probably the largest subgroup in the daily clinical praxis and randomized trials. Because survival was seldom prolonged, 'aggressive' combination therapy may only be necessary if the disease cannot be controlled by lower toxic and probably less effective monotherapy. A sequential approach rather than upfront combination chemotherapy has therefore been proposed as effective second-line salvage therapy is available in cases of disease progression (Table 5 ). Because quality of life has probably a higher preference than efficacy, infusional 5FU plus bevacizumab or capecitabine plus bevacizumab are options in this group of patients and in later lines of treatment irinotecan, oxaliplatin or the targeted agents may be used. This 'chemo light' option may be questioned now for patients with KRAS wild-type tumours. Patients with slow tumour progression or low tumour burden were most likely the majority in the CRYSTAL study. The median OS was prolonged by 3.5 months, which is supported in part by the PRIME and OPUS studies all indicating a difference of 3 months or more in median OS although failing statistical significance in the two latter trials. In the author's opinion these data support consideration of FOLFIRI plus cetuximab as a first-line treatment option for patients with KRAS wild-type tumours.
conclusions
Targeted agents have substantially improved and enriched the therapeutical armamentarium for our patients. This allows the treatment regimens to be adjusted to the treatment strategy, individual tumour biology and of course to the patient's needs considering the toxicity associated with a certain regimen. It is the art of the oncologist to choose the regimens accordingly.
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